COVID-19 Vaccines for Kids: Key Findings

This chapter explores the recent trials of COVID-19 vaccines for children aged 5 to 11 by Pfizer and BioNTech, showing positive responses to lower dosages. It also discusses the implications of these findings, including potential FDA approval timelines and the impact of COVID-19 on pediatric health.